In Vivo Therapeutics: The Future of CAR-T & CGT | ATW 2025
How are in vivo therapeutics shaping the future of cell and gene therapy? This session explores groundbreaking advancements in CAR-T therapies and the shift from ex vivo to in situ treatments.
💡 Highlights:
🧬 Ulf Grawunder discusses the promises & challenges of in vivo CAR-T therapies
🔄 Cecile Bauche explores the transition from ex vivo to in situ therapies
🚀 Bruce Levine outlines the next steps in the evolution of CAR-T treatments
🔎 Panel discussion & live Q&A with leading experts
Speakers:
🔹 Tony Ting – CSO, Kiji Therapeutics (Chair)
🔹 Ulf Grawunder – CEO, T-CURX
🔹 Cecile Bauche – CSO, Alaya.bio
🔹 Bruce Levine – Barbara & Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania
🎟️ Be part of the next wave of CGT innovation!
🔹 Pre-register for Advanced Therapies Week 2026 → https://ow.ly/5Ssp50Vaotw
📖 Download the ATW 2025 Show Brochure → https://ow.ly/raF450Vaouz
#ATW26 #InVivoTherapeutics #CART #CellAndGeneTherapy #ExVivo #InSitu #BiotechInnovation #AdvancedTherapies